Interleukin 32: Difference between revisions
CSV import |
CSV import |
||
| Line 27: | Line 27: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Revision as of 15:47, 17 March 2025
Interleukin 32 (IL-32) is a cytokine that plays a crucial role in immune responses. It is involved in various inflammatory processes and has been linked to several diseases, including rheumatoid arthritis, inflammatory bowel disease, and cancer.
Function
IL-32 is produced by T cells, natural killer cells, monocytes, and epithelial cells. It stimulates the production of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β), and it can also induce the expression of chemokines.
Clinical significance
IL-32 has been implicated in a number of diseases. It is overexpressed in the synovial fluid of patients with rheumatoid arthritis, and it has been suggested that it may play a role in the pathogenesis of this disease. In addition, IL-32 levels are elevated in the serum of patients with inflammatory bowel disease, suggesting that it may also be involved in the pathogenesis of this condition. Furthermore, IL-32 has been found to be overexpressed in various types of cancer, including breast cancer, lung cancer, and colorectal cancer.
Research
Research is ongoing to further understand the role of IL-32 in disease and to explore its potential as a therapeutic target. For example, studies are investigating the possibility of using IL-32 as a biomarker for disease activity in rheumatoid arthritis and inflammatory bowel disease. In addition, research is being conducted to determine whether targeting IL-32 could be a viable strategy for the treatment of cancer.


